b'R E L E A S E D I N D E C E M B E R , T H EI N S I G H T S A N D I M P A C T 2 0 2 1R E P O R T S H O W C A S E S O U R T H R E E - Y E A R P R O G R E S S A D V A N C I N G W O M E NA N D T R A N S F O R M I N G O U R I N D U S T R Y .D A T A F R O M T H E R E P O R T G A R N E R E D 4 6 9M E D I A M E N T I O N S T H A T R E A C H E D AC O L L E C T I V E A U D I E N C E O F 6 8 1 M I L L I O N .48 %From 2018 to 2020,the Collaborative doubled the representation of women SVPsjumping from 24 percent to 48 percentnearly achieving equal genderFrom 2018 to 2020 at therepresentation VP level and higher, HBA24 % at that level. Collaborative companies saw a27% AVERAGE In comparison, from 2018 to 2020, the broader pharmaceuticalINCREASEand medical product sector only increased representation of women SVPs from 25 percent to 32 percent.in womens representation,whereas the broader industry saw a2 HBA analysis of data from McKinsey & Companys Women in the Workplace2019, and 2020. Based on data from the start of each year.2018, 9 percent average decline.649 MEDIA USA TodayMENTIONS ForbesR E A C H I N G European Medical Journal GOLDMarketWatch+ In Vivo1B VIEWERS The Pink SheetPharmaceutical ExecutivePharmaVOICE2 0 2 1'